In this scenario, it is likely that the role of CD155 will change during tumor progression: In the early phases of transformation CD155 surface expression on tumor cells mainly promotes anti-tumor immune function while in the late phases it supports tumor growth and immune escape (Figure 1). Here, PVR is linked to neoplasm.